Atlas Trials

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

Clinical trial NCT02846766 · WITHDRAWN

Trial details

NCT number
NCT02846766
Sponsor
Teresa Helsten, MD
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Cancer
Start date
2018-07-01
Primary completion
2020-06-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.